BIOCAD sell "Prolgolimab"
Basic Information
1.1K
56
22
4.9(74)
Category
Subcategory & Sub-subcategory
Trade Type
Sell
Product Name
Prolgolimab
Specifications
- Formulation Type: Fully human anti-PD-1 monoclonal antibody
- Application: Indicated for treatment of advanced melanoma, advanced non-small cell lung cancer (NSCLC) and metastatic cervical cancer via PD-1 immune checkpoint blockade
- Regulatory Status: Approved in Russia for melanoma (from 2019); Phase III clinical trials ongoing to support EU marketing authorization
Other Information
Additional Description:
Prolgolimab is BIOCAD's original, fully human anti-PD-1 monoclonal antibody, developed for treating advanced melanoma, advanced NSCLC and metastatic cervical cancer. It is pending approval in Russia for melanoma from 2019, while BIOCAD pursues Phase III trials to support EU marketing authorisation.
Ratings
(0)
(0)
(0)
(0)
(0)
Comments
Filters:
Sort by:
No comments available.
Matched Products & Services
B2B matches based on trade type, category, specifications & price range
Similar Products & Services
Products & Services related to what you're viewing
People Also Viewed
Other products & services viewed by people who looked at this product
Leave your rating & comment